Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs. The reservoirs are unaffected by conventional HIV medication and invisible to the immune system. HDACi have the potential to activate these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response generate by Vacc-4x will be able to attack and eliminate the infected cells.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bionor Immuno AS
• Collaborator: Celgene Corporation
• Treatments: Histone Deacetylase Inhibitors; Romidepsin

Criteria

Inclusion Criteria:

1. Age >18 years

2. Currently receiving cART and having received cART for a minimum of 1 year

3. HIV-1 plasma RNA <50 copies/mL for at least 1 year (excluding viral load blips)

4. CD4 T cell count ≥500 cells/mm3

Exclusion Criteria:

1. CD4 T cell count nadir <200 cells/mm3

2. Previous treatment with an HDACi (Histone deacetylase inhibitor) within the previous 6 months

3. Any evidence of an active AIDS-defining opportunistic infection, active HBV or HCV co-infection, significant cardiac disease, malignancy, transplantation, insulin dependent diabetes mellitus or other protocol defined excluded medical condition

4. Use of any protocol defined contraindicated medication or vaccination

5. Unacceptable values of the hematologic and clinical chemistry parameters as defined in the protocol.

6. Males or females who are unwilling or unable to use protocol defined methods of contraception